

## TRADEMARK ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Envision Pharma Inc.		06/07/2013	CORPORATION: CONNECTICUT
RECEIVING PARTY DATA			
Name:	Madison Capital Funding LLC, as Agent		
Street Address:	30 South Wacker Drive, Suite 3700		
City:	Chicago		
State/Country:	ILLINOIS		
Postal Code:	60606		
Entity Type:	LIMITED LIABILITY COMPANY: DELAWARE		
PROPERTY NUMBERS Total: 4			
Property Type	Number	Word Mark	
Registration Number:	3257754	ENVISION PHARMA	
Registration Number:	3467830	VISIONTRACKER ENVISION PHARMA	
Serial Number:	85738638	DATAVISION	
Serial Number:	85738635	VISIONTRACKER	
CORRESPONDENCE DATA			
Fax Number:	3125774565		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	312-577-8265		
Email:	kristin.brozovic@kattenlaw.com		
Correspondent Name:	Kristin Brozovic c/o Katten		
Address Line 1:	525 W Monroe Street		
Address Line 4:	Chicago, ILLINOIS 60661		
ATTORNEY DOCKET NUMBER:	214338-103		
NAME OF SUBMITTER:	Kristin Brozovic		

CH \$115.00 3257754

TRADEMARK

Signature:	/Kristin Brozovic/
Date:	06/07/2013
Total Attachments: 5 source=Trademark Security Agreement (executed)#page1.tif source=Trademark Security Agreement (executed)#page2.tif source=Trademark Security Agreement (executed)#page3.tif source=Trademark Security Agreement (executed)#page4.tif source=Trademark Security Agreement (executed)#page5.tif	

## TRADEMARK SECURITY AGREEMENT

This TRADEMARK SECURITY AGREEMENT (this “**Agreement**”) made as of June 7, 2013, by Envision Pharma Inc., a Connecticut corporation (“**Grantor**”), in favor of Madison Capital Funding LLC, in its capacity as Agent for the Lenders (each as defined in the Credit Agreement referenced below) (in such capacity, “**Grantee**”):

### W I T N E S S E T H

WHEREAS, Envision Pharma Acquisition Inc., a Delaware corporation (“Holdings” or the “Initial Borrower”), upon the consummation of the Closing Date Acquisition and the execution and delivery by such Persons of a Borrower Joinder Agreement in accordance with the terms thereof, each of Envision Pharma Inc., a Connecticut corporation (“Envision Pharma”), Evidence Scientific Solutions, Inc., a Delaware corporation (“Evidence Scientific”), and UBC Scientific Solutions, Inc., a Delaware corporation (“UBC Scientific”; Envision Pharma, Evidence Scientific and UBC Scientific together with Initial Borrower, “Borrowers”), Initial Borrower (or, from and after the execution and delivery by Envision Pharma of a Borrower Joinder Agreement, Envision Pharma), as Borrower Representative, the financial institutions from time to time party thereto as Lenders and Grantee have entered into that certain Credit Agreement dated as of June 7, 2013 (as amended, restated, supplemented or otherwise modified from time to time, the “**Credit Agreement**”), pursuant to which Grantee and the Lenders have agreed, subject to the terms and conditions thereof, to make certain loans to, and other credit accommodations in favor of the Borrowers (collectively, the “**Loans**”).

WHEREAS, pursuant to the terms of that certain Guarantee and Collateral Agreement dated as of June 7, 2013, by and among Grantee, Grantor and the other Loan Parties from time to time party thereto (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “**Guarantee and Collateral Agreement**”), Grantor has granted to Grantee, for its benefit and the benefit of the Lenders, a security interest and lien upon substantially all assets of Grantor, including all right, title and interest of Grantor in, to and under all now owned and hereafter acquired Trademarks (as defined in the Guarantee and Collateral Agreement including registrations and applications therefore), together with the goodwill of the business symbolized by Grantor’s Trademarks, and all products and proceeds thereof, to secure the payment of all amounts owing by the Borrowers under the Credit Agreement.

NOW, THEREFORE, in consideration of the premises set forth herein and for other good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, Grantor agrees as follows:

1.     Incorporation of Credit Agreement and Guarantee and Collateral Agreement.  
The representations and warranties contained in the Credit Agreement and the Guarantee and Collateral Agreement to the extent applicable to Grantor are hereby incorporated herein in their entirety by this reference thereto. Unless otherwise noted herein, all capitalized terms used herein but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Guarantee and Collateral Agreement. In the event of a conflict between a provision of the Guarantee and Collateral Agreement and a provision of this Agreement, the provision of the Guarantee and Collateral Agreement shall control.

2. Grant and Reaffirmation of Grant of Security Interests. To secure the payment and performance of the Obligations (as defined in the Credit Agreement), Grantor hereby grants to Grantee, for its benefit and the benefit of the Lenders, and hereby reaffirms its prior grant pursuant to the Guarantee and Collateral Agreement of, a continuing security interest in Grantor's entire right, title and interest in and to the following (all of the following items or types of property being herein collectively referred to as the "**Trademark Collateral**"), whether now owned or existing or hereafter created, acquired or arising:

(a) each Trademark listed on Schedule A annexed hereto, together with any reissues, continuations or extensions thereof, and all of the goodwill of the business connected with the use of, and symbolized by, each such Trademark; and

(b) all products and proceeds of the foregoing, including without limitation, any claim by Grantor against third parties for past, present or future (i) infringement or dilution of each such Trademark, or (ii) injury to the goodwill associated with each such Trademark.


3. Intent-To-Use Trademarks. Notwithstanding the foregoing, and solely to the extent, if any, that, and solely during the period, if any, in which the grant of a security interest therein would impair the validity or enforceability of any registration that issues from such intent-to-use application under applicable federal law, the Trademark Collateral shall not include any applications filed in the United States Patent and Trademark Office to register trademarks or service marks on the basis of any Grantor's "intent to use" such trademarks or service marks unless and until the filing of a "Statement of Use" or "Amendment to Allege Use" has been filed and accepted, whereupon such applications shall be automatically subject to the security interest granted herein.

4. Governing Law. This Agreement is made under and governed by the laws of the State of New York applicable to contracts made and to be performed entirely within such State, without regard to conflict of laws principles.

*[Signature Page Follows]*

IN WITNESS WHEREOF, Grantor has duly executed this Agreement as of the date first written above.

**ENVISION PHARMA INC.,**  
a Connecticut corporation

By:   
Name: Scott Plumridge  
Title: Vice President

Agreed and accepted as of  
the date first written above:

**MADISON CAPITAL FUNDING LLC**, as  
Agent



By: \_\_\_\_\_

Name: Faraaz Kamran

Title: Managing Director

## SCHEDULE A

### Trademark Registrations

<b>Trademark</b>	<b>Registration Number</b>	<b>Registration Date</b>	<b>Jurisdiction</b>
DATAVISION	11235033	28-FEB-2013	European Community
VISIONTRACKER	11235066	28-FEB-2013	European Community
DATAVISION	638147	20-DEC-2012	Switzerland
VISIONTRACKER	638148	20-DEC-2012	Switzerland
	3257754	03-JUL-2007	United States
	3467830	15-JUL-2008	United States

### Trademark Applications

<b>Trademark</b>	<b>Application Number</b>	<b>Application Date</b>	<b>Jurisdiction</b>
DATAVISION	85738638	26-SEP-2012	United States
VISIONTRACKER	85738635	26-SEP-2012	United States